The UTX gene mutation was found to lead to an increased cancer risk, presenting a potential drug target for preventative therapies.
List view / Grid view
A drug target is anything within a living organism to which a drug is directed and/or binds, resulting in a change in its behaviour or function.
The team will receive $2 million over five years to investigate the CA2 brain region for the development of neurological therapies.
The intestine chip was infected with a coronavirus to test a variety of drugs, presenting a new method to investigate COVID-19 treatments.
Researchers discovered that cardiovascular damage was caused by reduced microRNA-210 levels in patient cells and mice with type 2 diabetes.
In a pre-clinical study, fibrinogen increased the death of mouse brain neurons, suggeting fibrin can have similar toxic effects on neurons.
The absence of interleukin-36 receptor antagonist (IL-36Ra) significantly slowed down wound healing in ischemia-reperfusion injuries in mice.
Scientists discover a long noncoding RNA, termed NXTAR, and a small molecule drug that could be used to treat prostate cancer.
Researchers used obese fruit flies to analyse how gene activities affect triacylglyceride levels, unveiling novel drug targets for obesity.
The peptide-centric chimeric antigen receptors killed neuroblastoma cells in mice and could potentially expand the pool of immunotherapeutic targets.
An experimental drug enhanced the benefit of immunotherapy, reducing and in some cases eliminating pancreatic cancer in mice.
The gene therapy restored the ability of neurons to convert levodopa to dopamine and may help develop therapies to slow disease progression.
Scientists revealed five proteins that cause blood vessel damage in COVID-19 patients, potentially leading to new drug targets.
Neutralising monoclonal antibodies protected aged macaque monkeys from SARS-CoV-2 and reduced inflammation, including in cerebrospinal fluid, a new study has shown.
Scientists have discovered a novel pathway and enzyme that causes thrombosis in chronic kidney disease (CKD) patients, indicating a new drug target.
Turning off NHE6 in mice in pre-clinical studies prevented amyloid beta aggregation, a key feature of Alzheimer's disease, pointing to new therapies.